Clinical Trial: A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma
Study Status: NOT_YET_RECRUITING
Recruit Status: NOT_YET_RECRUITING
Condition: Mantle Cell Lymphoma (MCL)
Study Type: INTERVENTIONAL
Official Title: A Multicentre, Phase II, Randomised, Open-label Study to Evaluate the Efficacy of Acalabrutinib in Combination With Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma (
Brief Summary:
TrAVeRse is a multicentre, open-label, randomised, Phase II study of AVR in treatment naïve MCL participants.The primary objective will be to assess the rate of MRD-negative CR at end of induction after completing 13 cycles of AVR.Participants achieving an MRD-negative CR at the end of AVR induction will be randomised to continued acalabrutinib or observation.Participants who progress during observation may receive retreatment with acalabrutinib
Read more